A study of Fermaglich and Miller (2023) evaluated trends in orphan drug designations and approvals after the Orphan Drug ...

an article from Kowal et al. (2023) In fact, it measures disparities in health outcomes. To do this, they use data from the American Community Survey ...

This is a key question if biologic drug prices are going to fall in the long term. We can decompose this question into 3 ...

The answer is "yes", but the question is in what way? an article from Che et al. (2024) examines the use of real-world data (RWD) in ETS evaluations from ...

ISPOR Europe starts this week in Barcelona, ​​Spain. In honor of ISPOR, I will summarize some key attributes of the ...

Cost-effectiveness analyzes (CEA) aim to examine how new healthcare technologies impact health outcomes and costs throughout a patient's life. While it is ...

That's the clever title of recient American Economic Review post by Cyrus Aghamolla, Pinar Karaca-Mandic, Xuelin Li, ...

Scoping reviews are a type of knowledge synthesis, following a systematic approach to mapping the evidence on a topic and ...

Randomized controlled trials are the gold standard for evaluating treatment effectiveness, but real-world effectiveness may vary. One reason for this is ...

That is the title of a KFF article published last week. Results are based on KFF. 2024 Employer Health Benefits Survey. ...